A detailed history of Acadian Asset Management LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Acadian Asset Management LLC holds 513,746 shares of QURE stock, worth $2.55 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
513,746
Previous 613,490 16.26%
Holding current value
$2.55 Million
Previous $3.19 Million 27.88%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$4.39 - $5.43 $437,876 - $541,609
-99,744 Reduced 16.26%
513,746 $2.3 Million
Q1 2024

May 10, 2024

BUY
$4.82 - $6.93 $1.69 Million - $2.43 Million
350,291 Added 133.09%
613,490 $3.19 Million
Q4 2023

Feb 13, 2024

BUY
$5.63 - $8.27 $1.48 Million - $2.18 Million
263,199 New
263,199 $1.78 Million
Q4 2022

Feb 14, 2023

SELL
$18.12 - $27.32 $553,566 - $834,626
-30,550 Reduced 94.34%
1,834 $41,000
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $1.01 Million - $1.52 Million
-59,614 Reduced 64.8%
32,384 $607,000
Q2 2022

Aug 09, 2022

SELL
$13.15 - $20.45 $229,796 - $357,363
-17,475 Reduced 15.96%
91,998 $1.72 Million
Q1 2022

May 12, 2022

BUY
$14.54 - $21.5 $1.43 Million - $2.11 Million
98,352 Added 884.38%
109,473 $1.98 Million
Q4 2021

Feb 10, 2022

SELL
$20.24 - $36.01 $898,230 - $1.6 Million
-44,379 Reduced 79.96%
11,121 $230,000
Q3 2021

Nov 12, 2021

BUY
$26.01 - $38.22 $1.44 Million - $2.12 Million
55,500 New
55,500 $1.77 Million
Q2 2018

Jul 24, 2018

SELL
$21.96 - $39.94 $123,195 - $224,063
-5,610 Closed
0 $0
Q1 2018

Apr 12, 2018

BUY
$17.1 - $26.61 $95,931 - $149,282
5,610 New
5,610 $132,000
Q4 2017

Jan 18, 2018

SELL
$9.47 - $19.59 $445,307 - $921,180
-47,023 Closed
0 $0
Q3 2017

Oct 13, 2017

BUY
$7.7 - $9.6 $362,077 - $451,420
47,023
47,023 $451,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $232M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.